For patients with early stage (I–II) NSCLC, the survival analysis demonstrated that high ezrin and ezrinThr-567 levels were associated with lower overall survival rate (P = 0.016 and P = 0.045, respectively, log-rank) (Figure 4). This evidence concerns the gene EZR and non-small cell lung carcinoma.